The Claim
Cytochrome P450 1B1 specifically promotes the differentiation and pathogenicity of pathogenic Th17 cells while not altering the generation of nonpathogenic Th17 cells in mice and humans with colitis.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
The enzyme Cytochrome P450 1B1 increases the development and harmful activity of a specific type of immune cell called pathogenic Th17 cells in colitis, but does not affect the formation of nonpathogenic Th17 cells.
See the scientific wording
Cytochrome P450 1B1 specifically influences the differentiation and pathogenicity of pathogenic Th17 cells without affecting nonpathogenic Th17 cell generation in mice and humans with colitis.
In inflamed gut tissue, a specific enzyme called CYP1B1 keeps levels of harmful molecules low inside certain immune cells. This allows the mitochondria in those cells to stay healthy and functional, which is required for the cells to become aggressive and cause damage. Without this enzyme, those harmful molecules build up, the mitochondria break down, and the aggressive immune cells cannot form or survive. Other types of immune cells in the same environment are not affected.
What the research says
1 studyIn people and mice with inflamed guts, a protein called CYP1B1 makes the bad version of a certain immune cell more active, but doesn’t touch the harmless version. Turning off this protein stops the bad cells without affecting the good ones.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.